Sincumar (acenocoumarol) tablets 2 mg. №50


Treatment and prevention of deep vein thrombosis and pulmonary artery embolism. Treatment of inhibitor defects (resistance to activated protein C, protein C and S deficiency, antithrombin i) and other thrombotic dispositions (such as anticardiolipin thrombosis syndrome and lupus anticoagulant thrombosis syndrome). Prevention of venous thrombosis of the thighs and knees in surgery. Thromboembolism prevention: at least 3 months prophylaxis of thromboembolism in case of acute myocardial infarction, if the following risk factors are appropriate: anterior Q infarction, severe left ventricular dysfunction (PV <35%), systemic or pulmonary thromboembolism t, by 2D echocardiography; in patients with atrial fibrillation, mitral valve disease, transient cerebral ischemia, or systemic embolization. Treatment and prevention of thromboembolism in patients with: atrial fibrillation, implanted mechanical, artificial valves, implanted biological artificial valves; severe dilated cardiomyopathy; peripheral artery occlusion or brain disease (stroke, transient ischemic attack) caused by embolism (may be unsuitable in case of acute period of hemorrhagic stroke confirmed by computed tomography).

Out of stock

Category: Manufacturer: Hungary


Composition and form of release
The active ingredient of Syncumar is acenocoumarol, excipients: lactose, talc, starch, magnesium stearate, gelatin.
Available in 2 mg tablets.
Syncumar is a medicine that reduces the activity of the blood coagulation system, preventing excessive blood clots.
It is indicated for use in blockage of blood vessels by a thrombus (thrombosis), inflammation of the vein wall with the formation of a thrombus (thrombophlebitis), movement of a thrombus (thromboembolism) in case of myocardial infarction and other diseases. In surgical practice, Syncumar is used to prevent thromboembolic complications after surgery.
Synumar is contraindicated in hemorrhagic diathesis or other diseases accompanied by reduced blood clotting, kidney failure, severe liver dysfunction, high blood pressure (hypertension), malignant neoplasms (cancer), diabetic retinal damage (retinopathy), physical exhaustion, low prothrombin level ( less than 70%), lack of vitamins K and C, continued bleeding from open wounds, stomach or intestinal ulcers (peptic ulcer, ulcerative colitis), cerebral hemorrhage (hemorrhagic stroke), threatened miscarriage, postpartum convulsions (eclampsia, preeclampsia), lingering inflammation walls of the heart (pericarditis or endocarditis), dissecting aneurysm (enlargement) of the aorta. Also, the drug should not be used after surgery on the eyes, brain or spinal cord, tooth extraction, lumbar (lumbar) puncture, aortic puncture, taking organ tissue samples (biopsy) for 4 days.
Application during pregnancy and lactation
Does not apply during these periods.
Method of administration and dosage
Syncumar is intended for oral administration. Sincumar is taken at the same time. The dose depends on the blood clotting parameters. Usually the initial dose is 6–8 mg x 1 time per day, then it is reduced to 4 mg x 1 time per day (under the control of the prothrombin time, which should be 2–3.5 s).
In case of an overdose with Syncumar, hemorrhagic diathesis is most often observed (bruising, blood in the urine, prolonged bleeding from superficial wounds, bleeding from the nose and gums, heavy menstruation) and prothrombin time is lengthened.
If signs of overdose occur, it is recommended to slowly inject 5–10 mg of vitamin K intravenously. For life-threatening bleeding, additionally transfuse fresh frozen plasma or a concentrate of a prothrombin complex containing factor VII.
Side effects
During the use of Sincumar tablets, nausea, loose stools, baldness, headache, allergic reactions (skin rash, redness, itching, swelling of the lips, eyelids, oral mucosa), bleeding, bruising, blood in the urine, bleeding from the gums, hematomas after strokes are possible. , the appearance of blood in the stool, heavy menstruation, accumulation of blood in the joint cavity (hemarthrosis).
Very rarely, necrosis (death) of the skin, subcutaneous tissue and purpuric feet syndrome (bluish hyperpigmentation of the feet and thumbs) may develop.
Possible withdrawal syndrome in the form of an increased risk of blood clots.
Storage conditions and periods
Syncumar must be stored at temperatures up to 30 ° C in its original packaging. Parents must ensure that medicines are not available to children.
Sinkumar shelf life is 5 years.